Lixumistat has completed Phase 1 studies in cancer patients and healthy subjects with a safety profile that supported a recommended Phase 2 dose. Clinical efficacy was demonstrated in a recently completed Phase 1b study of lixumistat in combination with gemcitabine/nab-paclitaxel in PDAC patients. ImmunoMet is raising capital to conduct key Phase 2 clinical studies with lixumistat.
Lixumistat is the only clinical-stage OxPhos inhibitor with demonstrated efficacy in pancreatic cancer. Phase 1 are complete with a safety profile that supports further development of Lixumistat. The Phase 1b/2a study at MD Anderson recently completed, with encouraging efficacy at the recommended Phase 2 dose.
"The current raise funds the path to proof of concept in PDAC and GBM, the two data inflection points that position ImmunoMet for partnering, licensing, or a next round."
Completed dose-escalation; no dose-limiting toxicities.
Recently completed at MD Anderson Cancer Centre.
Window-of-opportunity and Phase 2 planned.
For investor enquiries or to request the full investor deck, get in touch with our team.
